Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Abstract
OBJECTIVE Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes. Gevokizumab is a novel, human-engineered monoclonal anti–IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS In a placebo-controlled, dose-escalation study, a total of 98 patients were randomly assigned to placebo (17...
Paper Details
Title
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Published Date
Jul 14, 2012
Journal
Volume
35
Issue
8
Pages
1654 - 1662
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History